AngioDynamics (NASDAQ:ANGO) Lowered to “Strong Sell” Rating by Zacks Research

AngioDynamics (NASDAQ:ANGO) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Thursday,Zacks.com reports.

Several other research firms have also issued reports on ANGO. HC Wainwright increased their price objective on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday. Canaccord Genuity Group boosted their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Stock Performance

Shares of AngioDynamics stock opened at $13.51 on Thursday. The firm’s 50-day simple moving average is $12.24 and its 200-day simple moving average is $11.35. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $15.19. The firm has a market cap of $558.37 million, a P/E ratio of -15.53 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities analysts forecast that AngioDynamics will post -0.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AngioDynamics

A number of large investors have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in AngioDynamics by 262.7% during the 1st quarter. Bank of America Corp DE now owns 503,640 shares of the medical instruments supplier’s stock valued at $5,726,000 after purchasing an additional 364,763 shares in the last quarter. Quantinno Capital Management LP boosted its stake in AngioDynamics by 15.0% in the first quarter. Quantinno Capital Management LP now owns 43,539 shares of the medical instruments supplier’s stock worth $495,000 after purchasing an additional 5,675 shares in the last quarter. Lazard Asset Management LLC boosted its stake in AngioDynamics by 1,328.2% in the first quarter. Lazard Asset Management LLC now owns 154,578 shares of the medical instruments supplier’s stock worth $1,758,000 after purchasing an additional 143,755 shares in the last quarter. Paradigm Capital Management Inc. NY grew its holdings in shares of AngioDynamics by 5.9% during the first quarter. Paradigm Capital Management Inc. NY now owns 718,200 shares of the medical instruments supplier’s stock worth $8,166,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of AngioDynamics by 0.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock worth $8,624,000 after purchasing an additional 5,509 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on AngioDynamics and maintained a $19 price target, signaling confidence in the company’s longer-term upside despite ongoing losses. MarketBeat ANGO
• Positive Sentiment: An earlier report said AngioDynamics set a new 52-week high following an analyst upgrade, which likely reinforced bullish sentiment around the name. AngioDynamics Sets New 52-Week High Following Analyst Upgrade
• Neutral Sentiment: HC Wainwright cut several fiscal 2027 EPS estimates for AngioDynamics, including Q1, Q2, Q4, and full-year forecasts, reflecting a more cautious near-term earnings outlook. MarketBeat ANGO
• Neutral Sentiment: Despite the lower estimates, HC Wainwright still projects AngioDynamics will narrow losses over time, with FY2027 EPS estimated at ($0.27), close to the broader consensus of ($0.26). MarketBeat ANGO
• Negative Sentiment: A Seeking Alpha piece titled “AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)” suggests some analysts see limited upside after the recent run, which could temper enthusiasm. Seeking Alpha article

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.